



8-2-06

PTO/SB/21 (08-03)

1649

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/724,575
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1649
		Examiner Name	Daniel Kolker
Total Number of Pages in This Submission	16	Attorney Docket Number	15270J-005912US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form (1 page, submitted in duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (7 pages) with PTO/SB/08A Form (2 pages) and PTO/SB/08B Form (3 pages) and **copies of reference nos. 696-701, 727-729, 731-735, 737-738, 741-746, and 749-757 <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawings Sheets <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Return Receipt Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 19-4880.
**Not included in "Total Number of Pages in This Submission"		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Rosemarie L. Celli Reg. No. 42,397
Signature	<i>Rosemarie L. Celli</i>
Date	

CERTIFICATE OF MAILING	
I hereby certify that this correspondence and the documents referred to as attached therein are being deposited on July 31, 2006 with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee," mailing label No. EV 843 554 967 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Typed or printed name	Lilli Maddatu
Signature	<i>Lilli Maddatu</i>
Date	7/31/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180)

Complete if Known

Application Number	09/724,575
Filing Date	November 11, 2000
First Named Inventor	Dale B. Schenk
Examiner Name	Daniel Kolker
Art Unit	1649
Attorney Docket No.	15270J-005912US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 19-4880 Deposit Account Name: Sughrue Mion, PLLC

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility							
Design							
Plant							
Reissue							
Provisional							

2. EXCESS CLAIM FEES**Fee Description**

Small Entity
Fee (\$) Fee (\$)

Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent

Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent

Multiple dependent claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Fee (\$)	Fee Paid (\$)
_____ -20 or HP = _____	x _____	= _____				

HP = highest number of total claims paid for, if greater than 20

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
_____ -3 or HP = _____	x _____	= _____	

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
_____ - 100 = _____	/ 50 = _____	(round up to a whole number) x _____	= _____	

4. OTHER FEE(S)

Fees Paid (\$)

Non-English Specification, \$130 fee (no small entity discount)

Other: 1806 1.17(p) Submission of an Information Disclosure Statement

\$180

SUBMITTED BY

Signature	<i>Rosemarie L. Celli</i>	Registration No. (Attorney/Agent)	42,397	Telephone	650-625-8100
Name (Print/Type)	Rosemarie L. Celli			Date	<i>July 31, 2006</i>



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dale B. SCHENK

Docket No: 15270J-005912US

Appln. No.: 09/724,575

Group Art Unit: 1649

Confirmation No.: 6096

Examiner: Daniel Kolker

Filed: November 28, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASES

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97 and §1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence and the documents referred to as attached herein are being deposited on July 31, 2006 with the United States Postal Service in an envelope as "Express Mail Post Office To Addressee," mailing label No. EV 843 554 967 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

7/31/06
Date

Lilli Maddatu
Lilli Maddatu

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of references 696-701, 727-729, 731-735, 737-738, 741-746, and 749-757 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98; issued as U.S. 6,787,523 on 09/07/04;

09/497,553 filed 02/03/00;

09/724,477 filed 11/28/00; issued as U.S. 6,787,143 on 09/07/04;

09/723,927 filed 11/28/00; issued as U.S. 6,787,138 on 09/07/04;

Application No. 09/724,575
Supplemental Information Disclosure Statement filed July 31, 2006

09/723,762 filed 11/28/00; issued as U.S. 6,787,144 on 09/07/04 ;
09/724,102 filed 11/28/00; issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00; issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04; issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04; issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04; issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
11/108,102 filed 04/15/05;
11/245,524 filed 10/07/05;
10/934,609 filed 09/02/04; issued as U.S. 6,946,135 on 09/20/2005;
11/245,916 filed 10/7/05;
10/933,559 filed 09/02/04; issued as U.S. 6,972,127 on 12/06/05;
10/934,819 filed 09/02/04;
10/815,353 filed 03/31/04; issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04; issue fee paid 01/24/05;
10/815,404 filed 03/31/04; issued as U.S. 6,982,084 on 01/03/06;
10/884,892 filed 07/01/04; issued as U.S. 6,962,707 on 11/08/05;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00; issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;
10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;

Application No. 09/724,575
Supplemental Information Disclosure Statement filed July 31, 2006

10/923,605 filed 08/20/04;
10/923,267 filed 08/20/04;
10/923,469 filed 08/20/04;
09/724,940 filed 11/28/00; issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00; issued as U.S. 6,743,427 on 6/1/04;
10/823,463 filed 04/12/04;
11/058,757 filed 02/14/05;
11/396,391 filed 03/30/06;
09/580,018 filed 05/26/00; issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00; issued as U.S. 6,750,324 on 6/15/04;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,024 filed 04/12/04;
10/889,999 filed 04/12/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/723,765 filed 11/28/00;
10/822,968 filed 04/12/04;
09/724,567 filed 11/28/00; issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00; issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00; issued as U.S. 6,936,246 on 08/30/05;
09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed
05/26/00); and,
09/979,952 filed 04/09/02 (U.S. National Stage of PCT/US00/15239 filed
06/01/00); issued as U.S. 6,913,745 on 07/05/05.

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;

10/789,273 filed 2/27/04;

10/232,030 filed 08/30/02;

10/388,389 filed 03/12/03;

10/703,713 filed 11/07/03;

10/704,070 filed 11/07/03;

_____ filed 03/30/06;

10/388,214 filed 03/12/03;

10/858,855 filed 06/01/04;

10/771,174 filed 02/04/04;

11/260,047 filed 10/26/05;

11/304,986 filed 12/15/05;

11/305,889 filed 12/15/05;

60/637,253 filed 12/16/04;

11/305,899 filed 12/15/05;

11/303,478 filed 12/15/05;

11/304,072 filed 12/15/05;

60/736,119 filed 11/10/05;

60/691,821 filed 06/17/05;

60/735,687 filed 11/10/05;

10/544,093 filed 08/01/05 (U.S. National Stage of PCT/US04/02856 filed

01/31/04);

_____ filed 11/10/05;

_____ filed 11/10/05; and

_____ filed 01/27/06;

11/342,353 filed 01/27/06.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
09/580,015 filed 05/26/00;
09/580,019 filed 05/26/00;
09/724,291 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed

06/01/00);

09/579,690 filed 05/26/00;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99, and
09/723,544 filed 11/28/00.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;
60/444,150 filed 02/01/03;
60/616,474 filed 10/05/04;
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;

60/636,842 filed 12/15/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04;
60/736,045 filed 11/10/05;
60/648,631 filed 01/28/05;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03; and
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.


Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she are invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Application No. 09/724,575
Supplemental Information Disclosure Statement filed July 31, 2006

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 19-4880. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Registration No. 42,397

SUGHRUE MION, PLLC
Telephone: (650) 625-8100
Facsimile: (650) 625-8110

MOUNTAIN VIEW OFFICE

23493

CUSTOMER NUMBER

Date: July 31, 2006
60831825 v1
37041_1.DOC



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/724,575	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk	
			Art Unit	1649	
			Examiner Name	Daniel Kolker	
Sheet	1	of	5	Attorney Docket Number	15270J-005912US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	748	6,610,493	08-26-2003	Citron et al.	
	730	2003/0166557 A1	09-04-2003	Minna et al.	
	702	6,548,640	04-15-2003	Winter	
	725	6,538,124	03-25-2003	Idusogie et al.	
	726	6,528,624	03-04-2003	Idusogie et al.	
	710	6,407,213	06-18-2002	Carter et al.	
	720	6,277,375	08-21-2001	Ward	
	724	6,194,551	02-27-2001	Idusogie et al.	
	704	6,180,370	01-30-2001	Queen et al.	
	747	6,175,057	01-16-2001	Mucke et al.	
	719	6,165,745	12-26-2000	Ward et al.	
	723	6,121,022	09-19-2000	Presta et al.	
	711	6,054,297	04-25-2000	Carter et al.	
	722	5,869,046	02-09-1999	Presta et al.	
	707	5,859,205	01-12-1999	Adair et al.	
	705	5,693,761	12-02-1997	Queen et al.	
	721	5,677,425	10-14-1997	Bodmer et al.	
	717	5,648,260	07-15-1997	Winter et al.	
	718	5,624,821	04-29-1997	Winter et al.	
	706	5,585,089	12-17-1996	Queen et al.	
	703	5,225,539	07-06-1993	Winter	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/724,575	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk	
			Art Unit	1649	
			Examiner Name	Daniel Kolker	
Sheet	2	of	5	Attorney Docket Number	15270J-005912US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	738	EP	626 390	A1	11-30-1994			
	737	EP	620 276	A1	10-19-1994			
	701	WO	05/014041	A2	02-17-2005			
	757	WO	04/108895	A2, A3	12-16-2004			
	756	WO	03/016467	A2, A3	02-27-2003			
	696	WO	95/06407	A1	03-09-1995			
	736	WO	94/10569	A1	05-11-1994			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,575
				Filing Date	November 28, 2000
				First Named Inventor	Schenk
				Art Unit	1649
				Examiner Name	Daniel Kolker
Sheet	3	of	5	Attorney Docket Number	15270J-005912US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against β A4 Protein: A Potential Probe for Alzheimer's Disease," <u>Bioconjugate Chem.</u> , 5:119-125 (1994).		
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 <i>in Vivo</i> : Kinetics and Implications for Diagnosis and Therapy," <u>Cancer Research</u> , 47:4432-4443 (1987).		
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <u>J. Biol. Chem.</u> , 275(22):16941-16947 (2000).		
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999).		
	745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <u>Experimental Neurology</u> , 149:329-340 (1998).		
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.		
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991).		
	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <u>Int. J. Biochem. & Cell Biol.</u> , 35:1608-1613 (2003).		
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987).		
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985).		
	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <u>J. Molecular Neuroscience</u> , 24:105-113 (2004).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,575
				Filing Date	November 28, 2000
				First Named Inventor	Schenk
				Art Unit	1649
				Examiner Name	Daniel Kolker
Sheet	4	of	5	Attorney Docket Number	15270J-005912US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity & Aging</u> , 1:1-2 (2004).		
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).		
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).		
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).		
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).		
	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991).		
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996).		
	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α ," <u>PNAS</u> , 92:11294-11298 (1995).		
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).		
	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002).		
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,575
				Filing Date	November 28, 2000
				First Named Inventor	Schenk
				Art Unit	1649
				Examiner Name	Daniel Kolker
Sheet	5	of	5	Attorney Docket Number	15270J-005912US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.	
	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.